Mirati Therapeutics (BOVESPA:M2RT34) - Aandelenkoers, Nieuws & Analyse

M2RT34 Overzicht aandelen

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. Meer informatie

M2RT34 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 77.7% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 42.24% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Mirati Therapeutics, Inc. Concurrenten

Blau Farmacêutica

BOVESPA:BLAU3

R$2.6b

Biomm

BOVESPA:BIOM3

R$1.1b

Hypera

BOVESPA:HYPE3

R$12.8b

Bloomage BioTechnology

SHSE:688363

CN¥27.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Mirati Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$19.46
52 Week Hoogtepunt	US$21.64
52 Week Laag	US$9.00
Bèta	0.77
11 maand verandering	1.35%
3 maanden verandering	4.96%
1 Jaar Verandering	28.96%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-54.84%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	M2RT34	BR Biotechs	BR Markt
7D	0.6%	1.2%	0.9%
1Y	29.0%	9.3%	-0.4%

Rendement versus industrie: M2RT34 overtrof de BR Biotechs industrie, die het afgelopen jaar een rendement 9.3 % opleverde.

Rendement versus markt: M2RT34 overtrof de BR markt, die het afgelopen jaar een rendement opleverde van -0.4 %.

Prijsvolatiliteit

Is M2RT34's price volatile compared to industry and market?
M2RT34 volatility
M2RT34 Average Weekly Movement	1.7%
Biotechs Industry Average Movement	9.1%
Market Average Movement	4.4%
10% most volatile stocks in BR Market	8.1%
10% least volatile stocks in BR Market	2.3%

Stabiele aandelenkoers: M2RT34 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van M2RT34 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	587	Chuck Baum	www.mirati.com

Mirati Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Mirati Therapeutics zich tot de beurswaarde?
M2RT34 fundamentele statistieken
Marktkapitalisatie	R$20.53b
Inkomsten(TTM)	-R$3.62b
Inkomsten(TTM)	R$190.40m

107.8x

P/S-verhouding

-5.7x

Koers/Winstverhouding

Is M2RT34 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
M2RT34 resultatenrekening (TTM)
Inkomsten	US$38.19m
Kosten van inkomsten	US$510.48m
Brutowinst	-US$472.29m
Overige uitgaven	US$253.59m
Inkomsten	-US$725.88m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-10.35
Brutomarge	-1,236.66%
Nettowinstmarge	-1,900.65%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde M2RT34 op de lange termijn?

Bekijk historische prestaties en vergelijking

M2RT34 Overzicht aandelen

Beloningen

Risicoanalyse

Mirati Therapeutics, Inc. Concurrenten

BOVESPA:BLAU3

R$2.6b

BOVESPA:BIOM3

R$1.1b

BOVESPA:HYPE3

R$12.8b

SHSE:688363

CN¥27.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Mirati Therapeutics, Inc. Samenvatting

107.8x

-5.7x

Inkomsten en omzet